Prophylactic Therapy for Cytomegalovirus in Liver Transplant Recipients

• Status: Unknown status
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Null Hypothesis:

There is no significant difference in the incidence of CMV infection when using oral valganciclovir or ganciclovir as prophylactic anti-viral therapy.

Alternate Hypothesis:

There exists a significant difference in the incidence of CMV infection when oral valganciclovir is used for CMV prophylaxis rather than oral ganciclovir. A formal hypothesis to be tested should be defined.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oregon Health and Science University
• Treatments: Ganciclovir; Ganciclovir triphosphate; Valganciclovir

Criteria

Inclusion Criteria:

• All liver transplants will be performed at Oregon Health & Science University (OHSU) and the OHSU surgical and medical staff will treat patients.

Exclusion Criteria:

• Portland Veterans Affairs Medical Center liver transplant recipients

• Patients deceased within thirty days of receiving liver allograft

• Patients with low risk of acquiring CMV infection: donor-negative and recipient-negative (D-/R-)

• Patients undergoing re-transplantation

• Lost to follow-up (minimum follow-up is 1 year)

• History of CMV infection or disease

• Anti-CMV therapy within the past 30 d

• Severe, uncontrolled diarrhea or evidence of malabsorption.